

# Suspected brain metastasis from lung cancer mimicking intracerebral hemorrhage

# A case report

Rui Ma, MD, Shao-Kuan Fang, MD, PhD, Shuai Hou, MD, PhD, Xue Wang, MD, Hong-Mei Meng, MD, PhD $^{st}$ 

#### Abstract

Rationale: Hemorrhage rarely occurs in a solitary brain metastasis from lung carcinoma.

Patient concerns: We report on a 54-year-old man who presented with a severe headache for 4 days.

**Diagnoses:** Based on computed tomography and magnetic resonance imaging enhancement, the patient was diagnosed with a suspected hemorrhagic brain metastasis from lung carcinoma.

Interventions: The patient's family rejected a pathological examination.

Outcomes: The patient's family requested discharge after diagnosis.

**Lessons:** The present case emphasizes the need to consider hemorrhagic metastasis as a differential diagnosis in patients presenting with solitary intracerebral hemorrhage whose location is uncommon, especially when the poor general state of the patient cannot be attributed to hypertensive intracerebral hemorrhage.

**Abbreviations:** BM = brain metastasis, CSF = cerebrospinal fluid, CT = computed tomography, MRI = magnetic resonance imaging, MRV = magnetic resonance venography.

Keywords: brain metastasis, intracerebral hemorrhage, lung cancer

## 1. Introduction

Hemorrhagic brain metastasis (BM) from lung cancer manifests as multiple lesions with large edema and an irregular shape. The presence of both hemorrhagic lesions and non-hemorrhagic lesions in patients with multiple metastases is rare. Here, we report on a patient who presented with a solitary intracerebral hemorrhage, the cause of which was established as lung cancer metastasis. This emphasizes the importance of considering metastasis in a differential diagnosis of patients presented with only intracerebral hemorrhage.

## 1.1. Case Report

A 54-year-old man was admitted to the hospital for a severe headache. He reported a sudden headache presented with whole head pain, especially the frontal part, 4 days prior. He showed no

Editor: N/A.

RM and SKF have contributed equally to the article and were the co-first authors.

Department of Neurology and Neuroscience Center, First Hospital of Jilin University, Jilin, P.R. China.

<sup>\*</sup> Correspondence: Hong-Mei Meng, Department of Neurology and Neuroscience Center, First Hospital of Jilin University, 71, Xinmin Street, Changchun 130021, Jilin, P.R. China (e-mail: hongmeiyp@126.com).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2018) 97:10(e0106)

Received: 19 December 2017 / Received in final form: 12 February 2018 / Accepted: 16 February 2018

http://dx.doi.org/10.1097/MD.000000000010106

signs of blurred vision, diplopia, dizziness, nausea, vomiting, seizures, limb weakness, consciousness disturbance, or a recent, significant change in body weight. He reported no history of hypertension or familial history of cerebral hemorrhage. On admission, his blood pressure was 160/95 mmHg and his neurological examination was normal. The brain computed tomography (CT) scan showed hemorrhage in the left temporal occipital lobe (Fig. 1A). The CT angiography of the intracranial and cervical arteries showed no evidence of vascular malformation, aneurysm, or arteriovenous fistula. Brain magnetic resonance venography (MRV) revealed no obvious abnormalities. Laboratory test results were normal.

After dehydration to reduce intracranial pressure, nerve nutrition, and symptomatic treatment for 1 week did not relieve the symptoms. The general state of the patient, vision, and content of consciousness were significantly decreased. Cerebrospinal fluid (CSF) pressure was >400 mmH<sub>2</sub>O. Protein levels, cell count, and glucose in the CSF were normal and cytology showed no neoplastic cells.

Brain magnetic resonance imaging enhancement (Fig. 2) revealed a hemorrhagic lesion in the left temporal occipital lobe and bilateral ventricle, and multiple abnormal bilateral nodules. Lung CT scans revealed a high-density lesion in the right posterior lobe, located at the posterior basal segment of the bronchus, reminiscent of a malignant tumor (Fig. 1B). We administered mannitol, due to high cranial pressure, to reduce intracranial edema, pressure, and pain. We also recommended a pathological examination to define the nature of the lesions; his family refused and requested discharge.

## 2. Discussion

The most common reasons for hemorrhagic BM include melanoma, choriocarcinoma, renal cell carcinoma, and bronchogenic

The authors have no financial conflict of interest in the article.



Figure 1. Brain CT and lung CT. Brain CT (A) showed hemorrhage in the left temporal occipital lobe. Lung CT (B) showed a high density lesion in the right posterior lobe. CT = computed tomography.

carcinoma.<sup>[1]</sup> It is rare that hemorrhage occurs in a solitary BM from lung carcinoma. Because of the presence of multiple, abnormal bilateral nodules in both the brain and lungs, we considered hemorrhage to be caused by BM from the lung rather than hypertension. Since the patient refused surgical intervention, the diagnosis could not be confirmed without a biopsy.

The morbidity of BM is higher in patients with lung carcinoma than that of melanoma, breast cancer, renal cell carcinoma, and colorectal cancer.<sup>[2]</sup> Brain metastasis is found in 10% to 25% of lung cancer patients upon initial diagnosis where 40% to 50% of

lung cancer metastasized to the brain during the course of disease.<sup>[3]</sup> Although an occupied effect and peripheral edema may be seen in intracerebral hemorrhage (ICH), regardless of the cause, the location of bleeding may indicate its underlying etiology.<sup>[4]</sup>

The most common clinical symptom of BM upon initial diagnosis was a headache (25.2%), followed by motor dysfunction (20.5%), dizziness (5.8%), and seizure (3.5%). Cerebral lesions were asymptomatic at the time of the initial diagnosis of BM (50.8%).<sup>[5]</sup> Since these symptoms are easily confused with ICH, the diagnosis of BM can be missed.




Figure 2. Magnetic resonance imaging enhancement of brain. A–D showed a lesion in the left temporal occipital lobe and bilateral ventricle hemorrhage. E and F, Gadolinium-enhanced T1-weighted image. It shows several enhanced spots on the left frontal, parietal, and right temporal lobes.

The median survival time for untreated BM patients is 1 to 2 months, which may be extended to 6 months with radiotherapy and chemotherapy.<sup>[6]</sup> The present case emphasizes the need to consider hemorrhagic metastasis as a differential diagnosis in patients presenting with solitary intracerebral hemorrhage whose location is uncommon, especially when the poor general state of the patient cannot be explained by hypertensive intracerebral hemorrhage. Therefore, early diagnosis and active treatment are vital to improve prognosis and survival.

#### Acknowledgments

The authors thank to the patient for sharing his information and the consent for the publication was obtained.

#### References

- Mark SG. Intracerebral hemorrhage. Handbook of Neurosurgery 8th ed. Thieme Medical Publishers, New York:2016.
- [2] Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698–705.
- [3] Preusser M, Capper D, Ilhan-Mutlu A, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205–22.
- [4] Scott WR, New PF, Davis KR, et al. Computerized axial tomography of intracerebral and intraventricular hemorrhage. Radiology 1974;112:73–80.
- [5] Lee MH, Kong DS, Seol HJ, et al. Risk of seizure and its clinical implication in the patients with cerebral metastasis from lung cancer. Acta Neurochir (Wien) 2013;155:1833–7.
- [6] Fidler IJ. The biology of brain metastasis: challenges for therapy. Cancer J 2015;21:284–93.